Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

PFE 29.59 +0.10 (0.36%)
price chart
Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off
Having lost Lipitor, Viagra, and a number of other key therapies to generic competition in recent years, CEO Ian Read and Pfizer have made it clear that the company plans to grow its business organically and through acquisitions in order to get past ...
Pfizer Hasn't Ruled Out Potential Inversions, Chief Says  Wall Street Journal
Pfizer beats sales and profit forecasts, mum on future deals  Reuters UK
Related articles »  
UPDATE 2-Pfizer meningitis vaccine wins US approval
Oct 29 (Reuters) - Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis B, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S.
Pfizer Receives FDA Accelerated Approval for TRUMENBA� (Meningococcal ...  MarketWatch
Related articles »  
What Happens If Pfizer Inc. Doesn't Come Back For AstraZeneca plc?
Unfortunately, these figures imply that if Pfizer does not come back for Astra, Astra's shares will fall. If the company's valuation were to fall to a level similar to the rest of the sector, the shares would only be worth 3,523p. With earnings ...
Related articles »  
Stocks to Watch: Pfizer, DuPont, Whirlpool
Among the companies with shares expected to actively trade in Tuesday's session are Pfizer Inc., DuPont Co. and Whirlpool Corp.
Related articles »  
Pfizer Conference Call Highlights
Pfizer Inc. (NYSE: PFE) reported its third quarter earnings on Tuesday. Shares of the company are neutral. Below are some key highlights from its conference call.
BRIEF-Pfizer CEO says inversion deals still one potential option for company
Oct 28 (Reuters) - Pfizer Inc : * CEO says inversion deals still one potential option for company * CEO says still believes tax inversion deals, on case by case basis, can offer.
US court upholds patents on Pfizer's cancer drug
(Reuters) - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
Related articles »  
Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?
Big Pharma is undergoing a radical face-lift due to the avalanche of top-selling drugs losing patent protection. The consequences of the aptly named "patent cliff" have been widespread and immense in scope.
Pfizer Inc. (PFE): Why You Should Sell the Stock [AstraZeneca plc (ADR)]
buyers and sellers Lawrence Meyers: Pfizer Inc. (NYSE:PFE) is the country's largest prescription drug maker, has strong free cash flow, lots of cash, the third-highest dividend yield among the 30 Dow stocks, is attractively valued compared to its peer ...
Multiple Contraction Can Hit Pfizer (PFE)  Seeking Alpha (registration)
Related articles »  
Pfizer Announces It Will Buy Back $11 Billion in Shares
Pfizer Inc. (PFE) announced today it will buy $11 billion of its shares after walking away from a deal to acquire AstraZeneca Plc earlier this year.
Pfizer Approves $11B Stock Repurchase Plan  ABC News
Pfizer Approves $11B Stock Buyback; Reduces Hopes for AstraZeneca Bid  ValueWalk
Related articles »